FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s ATRA active Investigational New Drug (IND) applications.These INDs include the EBVALLO (tabelecleucel) program for patients two years of age and older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), as well as ATA3219, a CAR-T therapy for non-Hodgkin’s lymphoma and systemic lupus erythematosus.Specifically, identified subjects currently enrolled in the cli ...